Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00834119
Other study ID # P03270
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date September 1, 2003
Est. completion date April 1, 2004

Study information

Verified date February 2022
Source Organon and Co
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 4, non-comparative, open-label, multi-center study. It is designed to determine the effectiveness of regular intranasal steroid use in alleviating allergic rhinitis nasal symptoms, when used alone or in combination with an oral antihistamine. Subjects will receive 200 mcg (2 puffs in each nostril) of mometasone furoate once a day. An oral antihistamine at the discretion of the physician may be added at Day 28 (Visit 2), if patients fail to improve nasal symptoms.


Recruitment information / eligibility

Status Completed
Enrollment 72
Est. completion date April 1, 2004
Est. primary completion date April 1, 2004
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent form - Subjects must be between 18-65 years of age, of either sex and any race - Subjects must be diagnosed by the physician to have moderate to severe allergic rhinitis according to ARIA guidelines. - Subjects must be mometasone furoate naïve. Exclusion Criteria: - Significant comorbid medical condition. - Respiratory tract infection. - Any contraindications according to mometasone furoate product monograph. - Patients who have received antihistamine treatment within the last 5 days. - Patients who have received corticosteroid treatment within the last 30 days. - Patients who are likely to require the administration of systemic steroids during the course of this program. - Any condition which in the doctor's opinion could interfere with the patient completion of this program. - Pregnant or lactating patients. - Patients with local infections involving the nasal mucosa. - Patients with structural abnormalities or who have undergone nasal surgery or trauma in the past 6 months. - Patients with hypersensitivity to mometasone furoate or are allergic to corticosteroids. - Patients who are prone to nose bleeding.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Mometasone furoate
Mometasone furoate 200 mcg (2 puffs in each nostril) once a day for 28 days
Mometasone furoate
Mometasone furoate 200 mcg (2 puffs in each nostril) once a day plus an oral antihistamine added at Day 28 (Visit 2) at the discretion of the physician

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Organon and Co

Outcome

Type Measure Description Time frame Safety issue
Primary To assess the mean change in total nasal symptom score from Baseline to the Final Visit of regular intranasal steroid use (mometasone furoate) in allergic rhinitis patients when used alone or in combination with an oral antihistamine. Day 28 and Day 56
Secondary Patient satisfaction with intranasal steroid monotherapy. Day 28
Secondary Potential benefit of an oral antihistamine in combination with an intranasal steroid Day 56
See also
  Status Clinical Trial Phase
Completed NCT02424539 - A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 Microgram (mcg) and 110 mcg in Chinese Pediatric Subjects With Allergic Rhinitis (AR) Phase 4
Completed NCT02486159 - The Oligonucleotide Chip Analysis for Allergic Rhinitis Treatment in Herbal Plaster and Acupuncture N/A
Completed NCT00770315 - Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234) Phase 3
Completed NCT00771160 - MK0476 Study in Adult Patients With Perennial Allergic Rhinitis (0476-397)(COMPLETED) Phase 3
Recruiting NCT04435990 - Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites Phase 3
Recruiting NCT05177744 - Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
Recruiting NCT05621356 - Monitoring Allergen Immunotherapy in Allergic Rhinitis
Not yet recruiting NCT06330974 - Allergy, Asthma, and Atopic Eczema in Finland
Completed NCT03758456 - HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human Phase 1
Completed NCT04645979 - A Study to Learn What Participants Think of Treatment With Betamethasone Plus Loratadine to Treat Their Acute Allergic Rhinitis, Also Known as Hay Fever in Mexico
Completed NCT05122143 - Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers N/A
Completed NCT05901532 - Nasal Irrigation With Chinese Herbal Medicine as an Adjunctive Treatment in Allergic Rhinitis Phase 2
Terminated NCT02722083 - Exploratory Study for Allergy Relief Onset Phase 2
Recruiting NCT05656482 - Ability of a Cat Food to Reduce Respiratory Symptoms in Cat Allergic Patients
Recruiting NCT04898283 - Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses. Phase 3
Recruiting NCT06436534 - Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis N/A
Recruiting NCT05922176 - Biomarker Screening for Immunotherapy Response Evaluation Using Microneedle Patch in Patients With Allergic Rhinitis
Completed NCT02679105 - Intralymphatic Immunotherapy in Increasing Doses, After Subcutaneous Immunotherapy Phase 2/Phase 3
Completed NCT01104012 - Validation of Proteomic Analyses for Allergic Asthma and Rhinitis N/A
Completed NCT03375775 - Evaluation of Subcutaneous Immunotherapy Towards Pollen in Children N/A